Protagonist Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Protagonist Therapeutics, Inc. PTGX | 0.00 |
Protagonist Therapeutics (NASDAQ:PTGX) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$5.55m (up 33% from 2Q 2024).
- Net loss: US$34.8m (loss widened by 14% from 2Q 2024).
- US$0.55 loss per share (further deteriorated from US$0.50 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Protagonist Therapeutics EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 33%. Earnings per share (EPS) exceeded analyst estimates by 5.5%.
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
The company's shares are down 5.4% from a week ago.
Risk Analysis
Don't forget that there may still be risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.